Akash Maniam: The ADC Revolution Continues – Appreciating Structural and Toxicity Differences

Akash Maniam, Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared on LinkedIn about a recent paper by Yongmei Yin et al. published in Nature:

“The ADC revolution continues. Interesting seeing the toxicity differences between this and sacituzumab-govitecan. Emphasises how important the structures of ADCs are and why we should take the time to appreciate the differences between them.

That’s how we can make optimal clinical decisions on dosing, schedules and toxicity counselling.”

Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial

Authors: Yongmei Yin et al.